Jun 15, 2022 / 08:20PM GMT
Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division - VP
Good afternoon, everyone. Thanks for joining us. Really pleased to have Vertex with us today, and we have CEO, Reshma Kewalramani. With that, Reshma, I'm going to open it up to you if you have any opening comments, and then we can jump into questions.
Reshma Kewalramani - Vertex Pharmaceuticals Incorporated - CEO, President & Director
Sounds good. Salveen, thanks so much for the invitation. It's so good to be in person and in real life without a screen in front of us.
I wanted to make a couple of opening comments. The first was to say, I will make some forward-looking statements, and I refer you to our SEC disclosures to look through all of the risks. Maybe to start with Salveen, a couple of points about where we are as a company.
Vertex is at a new inflection point today with clear sustained leadership in CF, a pipeline that is broad and advanced with 5 programs that are now post proof of concept and a balance sheet that is strong and growing and allows us to
Vertex Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers